Deutsche Bank AG Grows Position in Xeris Biopharma Holdings, Inc. $XERS

Deutsche Bank AG raised its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 492.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 756,407 shares of the company's stock after purchasing an additional 628,807 shares during the quarter. Deutsche Bank AG owned approximately 0.48% of Xeris Biopharma worth $4,153,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. NewEdge Advisors LLC purchased a new stake in shares of Xeris Biopharma in the fourth quarter worth about $34,000. Raymond James Financial Inc. purchased a new stake in shares of Xeris Biopharma in the fourth quarter worth about $45,000. Two Sigma Advisers LP purchased a new stake in shares of Xeris Biopharma in the fourth quarter worth about $47,000. Aquatic Capital Management LLC purchased a new stake in shares of Xeris Biopharma in the fourth quarter worth about $50,000. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after buying an additional 3,847 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. HC Wainwright reissued a "buy" rating and issued a $10.00 price target on shares of Xeris Biopharma in a report on Tuesday, August 12th. Finally, Oppenheimer increased their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $6.58.

Insider Buying and Selling

In other Xeris Biopharma news, Director Dawn Halkuff sold 42,500 shares of Xeris Biopharma stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total transaction of $309,400.00. Following the transaction, the director directly owned 115,000 shares of the company's stock, valued at approximately $837,200. This trade represents a 26.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Kevin Mcculloch purchased 25,000 shares of the firm's stock in a transaction on Friday, June 13th. The shares were acquired at an average cost of $4.38 per share, for a total transaction of $109,500.00. Following the completion of the purchase, the insider directly owned 1,708,585 shares of the company's stock, valued at approximately $7,483,602.30. This represents a 1.48% increase in their position. The disclosure for this purchase can be found here. 4.56% of the stock is owned by company insiders.

Xeris Biopharma Trading Up 5.2%

XERS stock opened at $7.68 on Monday. The company's 50 day moving average is $5.23 and its 200 day moving average is $4.72. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -36.57 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 1-year low of $2.48 and a 1-year high of $7.72.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million. As a group, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.